Diabetes Drug Delivery Devices Market to Witness Promising Growth Opportunities by 2024-2035
Diabetes management relies heavily on reliable drug-delivery devices, including pen injectors, insulin pumps, and related systems. Rising global prevalence of diabetes continues to drive demand for more convenient, accurate, and connected delivery options.
At the core of this need is the Diabetes Drug Delivery Devices Market, valued at approximately USD 17–18 billion in 2025–2026 and projected to reach around USD 31 billion by 2030 at a CAGR of roughly 14%. Pen injectors and pumps remain major segments, with ongoing innovation in connected and automated systems.
Key players include Medtronic, Novo Nordisk, Roche, Ypsomed, and others. Continued growth in the diabetes population and preference for user-friendly devices will support expansion through the end of the decade.
Read More: https://www.rootsanalysis.com/reports/diabetes-drug-delivery-devices-market.html
Diabetes management relies heavily on reliable drug-delivery devices, including pen injectors, insulin pumps, and related systems. Rising global prevalence of diabetes continues to drive demand for more convenient, accurate, and connected delivery options.
At the core of this need is the Diabetes Drug Delivery Devices Market, valued at approximately USD 17–18 billion in 2025–2026 and projected to reach around USD 31 billion by 2030 at a CAGR of roughly 14%. Pen injectors and pumps remain major segments, with ongoing innovation in connected and automated systems.
Key players include Medtronic, Novo Nordisk, Roche, Ypsomed, and others. Continued growth in the diabetes population and preference for user-friendly devices will support expansion through the end of the decade.
Read More: https://www.rootsanalysis.com/reports/diabetes-drug-delivery-devices-market.html
Diabetes Drug Delivery Devices Market to Witness Promising Growth Opportunities by 2024-2035
Diabetes management relies heavily on reliable drug-delivery devices, including pen injectors, insulin pumps, and related systems. Rising global prevalence of diabetes continues to drive demand for more convenient, accurate, and connected delivery options.
At the core of this need is the Diabetes Drug Delivery Devices Market, valued at approximately USD 17–18 billion in 2025–2026 and projected to reach around USD 31 billion by 2030 at a CAGR of roughly 14%. Pen injectors and pumps remain major segments, with ongoing innovation in connected and automated systems.
Key players include Medtronic, Novo Nordisk, Roche, Ypsomed, and others. Continued growth in the diabetes population and preference for user-friendly devices will support expansion through the end of the decade.
Read More: https://www.rootsanalysis.com/reports/diabetes-drug-delivery-devices-market.html
